CURE’s kidney cancer page is an extensive resource of cancer information featuring the latest kidney cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on kidney cancer.
July 17th 2024
Relapse outcomes were similar in patients with high-risk renal cell carcinoma treated with Opdivo and with observation before and after surgery.
Cabometyx-Tecentriq Combo Shows Promise in Advanced Kidney Cancer
October 5th 2020“The combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) demonstrated encouraging clinical activity in previously untreated patients with advanced ccRCC,” Dr. Sumanta Kumar Pal, co-director of the Kidney Cancer Program at City of Hope in California, said during a presentation of the clear cell renal cell carcinoma cohort.
Opdivo-Yervoy Combination Shows Promise in Certain Patients with Previously Treated RCC
August 6th 2020While the combination of Opdivo and Yervoy is one of several treatment options for patients with metastatic renal cell carcinoma, many patients will likely progress after initial treatment. However, new research shows that when used after immune checkpoint inhibition, the combination shows promise.
Combination of Avastin and Tarceva 'Should Be Considered Preferred Option' in Kidney Cancer Subtype
July 10th 2020Data from a phase 2 study presented during the 2020 ASCO Virtual Scientific Program demonstrated that Avastin (bevacizumab) in combination with Tarceva (erlotinib) was well tolerated and produced encouraging clinical outcomes in patients with advanced hereditary leiomyomatosis and renal cell carcinoma or sporadic papillary renal cell carcinoma.
FDA Approves Every Six-Week Dose of Keytruda Across All Indicated Cancer Types
April 29th 2020Keytruda, an immunotherapy that treats a variety of adult cancers, can now be given at a higher dose that requires fewer visits to clinics for infusions to support social distancing during the COVID-19 pandemic.